Our Access Briefing Q3-2025 shows interesting insights from Germany.

 

In the third quarter of this year, we delivered several decisions and exciting developments from the German HTA landscape. Read a brief summary here 👇️

 

 The highlights:

🏛️ One assessment as known substance in new therapeutic (and paediatric) indication with new regulatory data protection

➡️ Three evidence transfers from older to younger patients, of which one is accepted

✅ Considerable additional benefit based on adjusted indirect comparison

💊 Implementation of the appropriate comparator "individual therapy" with a single comparator study due to slicing

🚀 Naive comparison of Exagamglogen autotemcel (first drug based on the innovative CRISPR/Cas Method (Nobel Price in 2020 for the technology)) with standard of care population shows dramatic effect in transfusion independence (89.9% vs. 0%!)

 

The stats:

❌ Additional benefit is not proven: 16 (50%)

⭕️ Non quantifiable additional benefit: 7 (22%)

👌 Minor additional benefit: 5 (16%)

👍 Considerable additional benefit: 4 (12%)

 

📝 Register here to receive the latest and upcoming issues of the complete Access Briefing with HTA insights from 13 countries, compiled by 8 partners of our network 👉 https://forms.office.com/e/Jt8bPmVkdJ